Stryker (NYSE:SYK) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Stryker (NYSE:SYK – Get Rating) in a research note released on Thursday. The brokerage issued a buy rating on the medical technology company’s stock.

A number of other research analysts have also recently issued reports on SYK. Argus increased their target price on shares of Stryker from $270.00 to $285.00 and gave the company a buy rating in a report on Tuesday, February 21st. Wells Fargo & Company raised their price objective on Stryker from $281.00 to $285.00 and gave the company an overweight rating in a research note on Wednesday, February 1st. TheStreet raised Stryker from a c+ rating to a b rating in a research note on Tuesday, November 22nd. Evercore ISI raised their price objective on Stryker to $265.00 in a research note on Tuesday, January 3rd. Finally, Barclays raised their price objective on Stryker from $265.00 to $283.00 and gave the company an overweight rating in a research note on Thursday, February 2nd. Seven investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of Moderate Buy and an average price target of $270.79.

Stryker Trading Down 0.3 %

NYSE SYK opened at $274.44 on Thursday. The stock has a market capitalization of $103.97 billion, a P/E ratio of 44.48, a P/E/G ratio of 2.82 and a beta of 0.93. Stryker has a 52-week low of $188.84 and a 52-week high of $284.00. The firm has a 50-day moving average price of $263.78 and a 200 day moving average price of $238.53. The company has a quick ratio of 1.00, a current ratio of 1.63 and a debt-to-equity ratio of 0.71.

Stryker (NYSE:SYK – Get Rating) last posted its quarterly earnings results on Tuesday, January 31st. The medical technology company reported $3.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.84 by $0.16. The firm had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $4.97 billion. Stryker had a net margin of 12.78% and a return on equity of 22.39%. The firm’s revenue for the quarter was up 10.7% on a year-over-year basis. During the same period in the prior year, the company posted $2.71 earnings per share. Equities research analysts expect that Stryker will post 10.02 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, April 28th. Shareholders of record on Friday, March 31st will be given a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a yield of 1.09%. The ex-dividend date of this dividend is Thursday, March 30th. Stryker’s payout ratio is 48.62%.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 307,800 shares of the firm’s stock in a transaction on Monday, February 6th. The stock was sold at an average price of $273.91, for a total transaction of $84,309,498.00. Following the sale, the director now owns 4,942,954 shares in the company, valued at $1,353,924,530.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Allan C. Golston sold 5,459 shares of the firm’s stock in a transaction on Tuesday, February 28th. The stock was sold at an average price of $263.27, for a total transaction of $1,437,190.93. Following the sale, the director now owns 13,537 shares in the company, valued at $3,563,885.99. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronda E. Stryker sold 307,800 shares of the firm’s stock in a transaction on Monday, February 6th. The stock was sold at an average price of $273.91, for a total value of $84,309,498.00. Following the sale, the director now owns 4,942,954 shares in the company, valued at approximately $1,353,924,530.14. The disclosure for this sale can be found here. Insiders have sold 357,410 shares of company stock worth $97,831,003 over the last quarter. 6.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Stryker

Several hedge funds have recently made changes to their positions in SYK. AMG National Trust Bank boosted its holdings in Stryker by 18.0% in the third quarter. AMG National Trust Bank now owns 18,650 shares of the medical technology company’s stock valued at $3,778,000 after acquiring an additional 2,851 shares during the last quarter. J.W. Cole Advisors Inc. boosted its holdings in Stryker by 5.0% in the third quarter. J.W. Cole Advisors Inc. now owns 2,757 shares of the medical technology company’s stock valued at $558,000 after acquiring an additional 132 shares during the last quarter. Asset Dedication LLC acquired a new position in Stryker in the third quarter valued at $184,000. First Merchants Corp boosted its holdings in Stryker by 4.3% in the third quarter. First Merchants Corp now owns 59,837 shares of the medical technology company’s stock valued at $12,119,000 after acquiring an additional 2,486 shares during the last quarter. Finally, Orion Portfolio Solutions LLC boosted its holdings in Stryker by 26.9% in the third quarter. Orion Portfolio Solutions LLC now owns 1,956 shares of the medical technology company’s stock valued at $396,000 after acquiring an additional 415 shares during the last quarter. Institutional investors and hedge funds own 77.10% of the company’s stock.

About Stryker

(Get Rating)

Stryker Corp. is a medical technology company, which engages in the provision of innovative products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery.